-
Takeda Pharmaceutical Co., LTD et al v. Handa Pharmaceuticals, LLC DC CAFC
- 3:11-cv-00840
- N.D. Cal.
- Judge: Joseph C. Spero
+1
- Filed: 02/23/2011
- Closed: 11/01/2013
- Latest Docket Entry: 01/03/2024
- PACER
- Docket updated daily
4
Plaintiffs
3
Defendants
1
Accused
Product
6
Patents-in-Suit
983
Days in
Litigation
-
Takeda Pharmaceutical Co., LTD et al v. Handa Pharmaceuticals, LLC DC CAFC
- 3:11-cv-00840
- N.D. Cal.
- Judge: Joseph C. Spero
+1
- Filed: 02/23/2011
- Closed: 11/01/2013
- Latest Docket Entry: 01/03/2024
- PACER
- Docket updated daily
Causes of Action
Infringement
Declaratory Judgment
Patent Invalidity
Patent Non-Infringement
Patent Unenforceability
Patent Non-Infringement
Patent Unenforceability
Market Sector
Biotech and Pharma
Assigned Judge
Previously Presiding
Charles R. Breyer (until 12/18/2011)
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
An amorphous compound of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof.
|
Enforceable and Valid
Entry 451 |
| 2 |
A pharmaceutical composition comprising the amorphous compound according to claim 1 and a pharmaceutically acceptable excipient, carrier or diluent.
|
Enforceable and Valid
Entry 451 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Valid (103)
Entry 446 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
A crystalline compound of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole.
|
Enforceable and Valid (103)
Entry 451 Entry 446 |
| 3 |
A pharmaceutical composition comprising:</claim-text> a crystalline compound of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof; and a pharmaceutically acceptable excipient, carrier or
view more
|
Enforceable and Valid (103)
Entry 451 Entry 446 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A crystal of (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole wherein the X-ray powder diffraction analysis pattern has characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09,
view more
|
Valid (103)
Entry 446 |
| 3 |
A pharmaceutical composition which comprises the crystal according to claim 1 and a pharmaceutically acceptable excipient, carrier or diluent.
|
Valid (103)
Entry 446 |
-
Infringement
Handa Pharmaceuticals LLC
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 30 mg, 60 mg dosage of dexlansoprazole delayed release capsules Abbreviated New Drug Application No. 202-294Crystalline dexlansoprazole | US 6,664,276 B2 |
2, 3
|
Infringement
Entry 451Entry 446 |
| 30 mg, 60 mg dosage of dexlansoprazole delayed release capsules Abbreviated New Drug Application No. 202-294 | US 7,737,282 B2 |
1, 2
|
Infringement
Entry 451
|
| 30 mg, 60 mg dosage of dexlansoprazole delayed release capsules Abbreviated New Drug Application No. 202-294 | US 7,790,755 B2 |
2, 4, 6
|
No infringement
Entry 451
|
Par Pharmaceutical, Inc.
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 30 mg, 60 mg dosage of dexlansoprazole delayed release capsules Abbreviated New Drug Application No. 202-294 | US 6,664,276 B2 |
2, 3
|
Infringement
Entry 451
|
| 30 mg, 60 mg dosage of dexlansoprazole delayed release capsules Abbreviated New Drug Application No. 202-294 | US 7,737,282 B2 |
1, 2
|
Infringement
Entry 451
|
| 30 mg, 60 mg dosage of dexlansoprazole delayed release capsules Abbreviated New Drug Application No. 202-294 | US 7,790,755 B2 |
2, 4, 6
|
No infringement
Entry 451
|
